UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.

MLA

Benjamin, Reuben, et al. “UCART19, a First-in-Class Allogeneic Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (CALM): A Phase 1, Dose-Escalation Trial.” The Lancet. Haematology, vol. 9, no. 11, Nov. 2022, pp. e833–43. EBSCOhost, https://doi.org/10.1016/S2352-3026(22)00245-9.

APA

Benjamin, R., Jain, N., Maus, M. V., Boissel, N., Graham, C., Jozwik, A., Yallop, D., Konopleva, M., Frigault, M. J., Teshima, T., Kato, K., Boucaud, F., Balandraud, S., Gianella-Borradori, A., Binlich, F., Marchiq, I., Dupouy, S., Almena-Carrasco, M., Pannaux, M., … Mohty, M. (2022). UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. The Lancet. Haematology, 9(11), e833–e843. https://doi.org/10.1016/S2352-3026(22)00245-9

Chicago

Benjamin, Reuben, Nitin Jain, Marcela V Maus, Nicolas Boissel, Charlotte Graham, Agnieszka Jozwik, Deborah Yallop, et al. 2022. “UCART19, a First-in-Class Allogeneic Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (CALM): A Phase 1, Dose-Escalation Trial.” The Lancet. Haematology 9 (11): e833–43. doi:10.1016/S2352-3026(22)00245-9.